



<div style="text-align: center;">  <p>FORM PTO/SB-08A (REV. 10-96)</p> <p>Substitute for form PTO 449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use several sheets if necessary)</p> <p>Sheet <u>1</u> of <u>1</u></p> </div>	Complete if Known	
	Application Number	10/ 263,330
	Filing Date	October 2, 2002
	First Named Inventor	FRANZOSO, Guido, <i>et al.</i>
	Group Art Unit	1645
	Examiner Name	Not Yet Assigned
Attorney Docket Number	21459-93823	

B OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹		T ²
A/no	B.1	DE SMAELE, Enrico, <i>et al.</i> (2001) "Induction of <i>gadd45</i> by NF- κ B Downregulates Pro-apoptotic JNK Signaling." Letters to Nature. 414: 308-313.	
	B.2	DINKOVA-KOSTOVA, Albena T., <i>et al.</i> (2001) "Potency of Michael Reaction Acceptors as Inducers of Enzymes That Protect Against Carcinogenesis Depends on Their Reactivity With Sulfhydryl Groups." PNAS. 98: 3404-3409.	
	B.3	JIN, Ronguan, <i>et al.</i> (2002) "Regulation of the <i>gadd45</i> Promoter by NF- κ B." DNA and Cell Biology. 21: 491-503.	
	B.4	PETER, Marcus E., <i>et al.</i> (1998) "Mechanisms of CD95 (APO-1/Fas)-mediated Apoptosis." Current Opinion in Immunology 10: 545-551.	
	B.5	RAMOS-GOMEZ, Minerva, <i>et al.</i> (2001) "Sensitivity to Carcinogenesis is Increased and Chemoprotective Efficacy of Enzyme Inducers is Lost in <i>nrf2</i> Transcription Factor-Deficient Mice." PNAS 98: 410-3415.	
	B.6	SCAFFIDI, Carsten, <i>et al.</i> (1998) "Two CD95 (APO-1/Fas) Signaling Pathways." The EMBO Journal. 17: 1675-1687.	
	B.7		
	B.8		
	B.9		
	B.10		
	B.11		
	B.12		

EXAMINER 	DATE CONSIDERED 02/17/06
--	--------------------------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231

Submitted to the Office 06/30/2003

FORM PTO/SB 08A
(REV. 10-96)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Sheet 1 of 4

Complete if Known

Application Number:	10/ 263,330
Filing Date:	October 2, 2002
First Named Inventor:	FRANZOSO, Guido, <i>et al.</i>
Group Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number:	21459-93823

A

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A.1				
	A.2				
	A.3				
	A.4				
	A.5				
	A.6				
	A.7				
	A.8				
	A.9				
	A.10				
	A.11				
	A.12				
	A.13				
	A.14				
	A.15				
	A.16				
	A.17				
	A.18				
	A.19				

FOREIGN PATENT DOCUMENTS

Examine r Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
ASP	A.20	WO 84/03564	09-13-1984	GEYSEN, Hendrik <i>et al.</i>		
	A.21					
	A.22					
	A.23					
	A.24					

EXAMINER

DATE CONSIDERED

02/17/06

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Send to: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO/SB/CBA (REV. 10-96) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Substitute for form PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) Sheet <u>2</u> of <u>4</u>	Complete if Known	
	Application Number	10/ 263,330
	Filing Date	October 2, 2002
	First Named Inventor	FRANZOSO, Guido, <i>et al.</i>
	Group Art Unit	1645
	Examiner Name	Not Yet Assigned
Attorney Docket Number	21459-93823	

A OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹		T ²
ASP	A.1	Beg, Amer A. and Baltimore, David (1996) "An Essential Role for NF- κ B in Preventing TNF- α -Induced Cell Death" <i>Science</i> 274 (5288):782.	
	A.2	Budihardjo, I., <i>et al.</i> (1999) "Biochemical Pathways of Caspase Activation During Apoptosis" <i>Annu. Rev. Cell Dev. Biol.</i> 15:269-90.	
	A.3	Chang, Lufen and Karin, Michael (2001) "Mammalian MAP Kinase Signalling Cascades" <i>Nature</i> 410(6824):37-40.	
	A.4	Davis, Roger J. (2000) "Signal Transduction by the JNK Group of MAP Kinases" <i>Cell</i> 103:239-252.	
	A.5	Franzoso, Guido, <i>et al.</i> (1992) "The Candidate Oncoprotein Bcl-3 is an Antagonist of p50/NF- κ B-Mediated Inhibition" <i>Nature</i> 359:339-359.	
	A.6	Franzoso, Guido, <i>et al.</i> (2003) "JNK: A Killer on a Transcriptional Leash" <i>Cell Death and Differentiation</i> 10:13-15.	
	A.7	Gerlach, Wayne L., <i>et al.</i> (1987) "Construction of a Plant Disease Resistance Gene from the Satellite RNA of Tobacco Ringspot Virus" <i>Nature</i> 328:802-805.	
	A.8	Ghosh, Sankar, <i>et al.</i> (1998) "NF- κ B and Rel Proteins: Evolutionarily Conserved Mediators of Immune Responses" <i>Annu. Rev. Immunol.</i> 16:225-60.	
	A.9	Guo, Yan-Lin, <i>et al.</i> (1998) "Correlation Between Sustained c-Jun N-terminal Protein Kinase Activation and Apoptosis Induced by Tumor Necrosis Factor- α in Rat Mesangial Cells" <i>The Journal of Biological Chemistry</i> 273, 13:4027-4034.	
	A.10	Heinemeyer, T., <i>et al.</i> (1999) "Expanding the TRANSFAC Database Towards an Expert System of Regulatory Molecular Mechanisms" <i>Nucleic Acids Research</i> 27, 1:318-322.	
	A.11	Huang, Shuang, <i>et al.</i> (1997) "Apoptosis Signaling Pathway in T Cells Is Composed of ICE/Ced-3 Family Proteases and MAP Kinase Kinase 6b" <i>Immunity</i> 6:739-749.	
	A.12	Johanson, Kyung, <i>et al.</i> (1995) "Binding Interactions of Human Interleukin 5 with Its Receptor α Subunit" <i>The Journal of Biological Chemistry</i> 270, 16:9459-9471.	

EXAMINER	DATE CONSIDERED	02/17/06
----------	-----------------	----------


*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Submitted to the Office 06/30/2003

FORM PTO/SB/08A (REV. 10-96) Substitute for form PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) Sheet <u>3</u> of <u>4</u>	Complete if Known	
	Application Number	10/ 263,330
	Filing Date	October 2, 2002
	First Named Inventor	FRANZOSO, Guido, <i>et al.</i>
	Group Art Unit	1645
	Examiner Name	Not Yet Assigned
Attorney Docket Number		21459-93823

A OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹		T ²
ASD	B.1	Kim, Sung-Hou and Cech, Thomas R. (1987) "Three-Dimensional Model of the Active Site of the Self-Splicing rRNA Precursor of Tetrahymena" <i>Biochemistry</i> 84:8788-8792.	
	B.2	Lin, Anning, <i>et al.</i> (1995) "Identification of a Dual Specificity Kinase Activities the Jun Kinases and p38-Mpk" <i>Science</i> 268:286-290.	
	B.3	Liu, Zheng-gang, <i>et al.</i> (1996) "Dissection of TNF Receptor 1 Effector Functions: JNK Activation is Not Linked to Apoptosis While NF- κ B Activation Prevents Cell Death" <i>Cell</i> 87:565-576.	
	B.4	Medema, Jan Paul, <i>et al.</i> (1997) "FLICE is Activated by Association with the CD95 Death-Inducing Signaling Complex (DISC)" <i>The EMBO Journal</i> 16, 10:2794-2804.	
	B.5	Michel, Francois and Westhof, Eric (1990) "Modelling of the Three-Dimensional Architecture of Group I Catalytic Introns Based on Comparative Sequence Analysis" <i>J. Mol. Biol.</i> 216:585-610.	
	B.6	Mitchell, M.S., <i>et al.</i> (1993) "Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates. Rationale, Results, and Possible Mechanisms of Action" <i>Ann. N.Y. Acad Sci</i> 690,1: 153-166.	
	B.7	Mitchell, Malcolm S., <i>et al.</i> (1990) "Active-Specific Immunotherapy for Melanoma" <i>Journal of Clinical Oncology</i> 8, 5: 856-869.	
	B.8	Morton, Bennett D., <i>et al.</i> (1995) "Kinetic Characterization of the Interaction of Biotinylated Human Interleukin 5 with an Fc Chimera of its Receptor Alpha Subunit and Development of an ELISA Screening Assay Using Real-Time Interaction Biosensor Analysis" <i>J. Mol. Recognit</i> 8, 1-2: 52-8.	
	B.9	Morton, Donald, L. and Barth, Andreas (1996) "Vaccine Therapy for Malignant Melanoma" <i>CA-A Cancer Journal for Clinicians</i> 46, 4: 225-244.	
	B.10	Reinhold-Hurek, Barbara and Shub, David A. (1992) "Self-Splicing Introns in tRNA Genes of Widely Divergent Bacteria" <i>Nature</i> 357: 173-176.	
	B.11	Rosenberg, Steven A., <i>et al.</i> (1988) "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 In the Immunotherapy of Patients with Metastatic Melanoma" <i>The New England Journal of Medicine</i> 319, 25: 1676-1680.	
	B.12	Rovere, Patrizia <i>et al.</i> (1999) "Dendritic Cell Presentation of Antigens From Apoptotic Cells in a Proinflammatory Context" <i>Arthritis & Rheumatism</i> 42, 7: 1412-1420.	

EXAMINER 	DATE CONSIDERED	02/12/06
--	-----------------	----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO/SB/08A (REV. 10-96) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Substitution for form 1449A-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) Sheet <u>4</u> of <u>4</u>	Complete if Known	
	Application Number	10/ 263,330
	Filing Date	October 2, 2002
	First Named Inventor	FRANZOSO, Guido, <i>et al.</i>
	Group Art Unit	1645
	Examiner Name	Not Yet Assigned
Attorney Docket Number	21459-93823	

B	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹		T ²
A. SP	C.1	Scaffidi, Carsten <i>et al.</i> (1999) "Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells" <i>The Journal of Biological Chemistry</i> 274, 32: 22532-22538.	
	C.2	Stegh, Alexander H., <i>et al.</i> (2000) "Identification of the Cytolinker Plectin as a Major Early In Vivo Substrate for Caspase 8 During CD95- and Tumor Necrosis Factor Receptor-Mediated Apoptosis" <i>Molecular and Cellular Biology</i> 20, 15: 5665-5679.	
	C.3	Steinman, Ralph M., <i>et al.</i> (1999) "Antigen Capture, Processing, and Presentation by Dendritic Cells: Recent Cell Biological Studies" <i>Human Immunology</i> 60: 562-567.	
	C.4	Tatusova, Tatiana A., <i>et al.</i> (1999) "Complete Genomes in WWW Entrez: Data Representation and Analysis" <i>Bioinformatics</i> 15, 7/8: 536-543.	
	C.5	Van Antwerp, Daniel J., <i>et al.</i> (1996) "Suppression of TNF- α -Induced Apoptosis by NF- κ B" <i>Science</i> 274 (5288): 787.	
	C.6	Vito, Pasquale <i>et al.</i> (1996) "Interfering With Apoptosis: Ca ²⁺ - Binding Protein ALG-2 and Alzheimer's Disease Gene ALG-3" <i>Science</i> 271 (5248): 521.	
	C.7	Wang, Xiantao <i>et al.</i> (1999) "gadd In not Required for Activation of c-Jun N-terminal Kinase or p38 During Acute Stress" <i>The Journal of Biological Chemistry</i> 274, 42: 29599-29602.	
	C.8	Yang, Jianfei <i>et al.</i> (2001) "IL-18-Stimulated GADD45 β Required in Cytokine-induced, but not TCR-induced, IFN- γ Production" <i>Nature Immunol</i> 2, 2: 157-164.	
	C.9		
	C.10		
	C.11		
	C.12		

EXAMINER	DATE CONSIDERED	02/17/06
----------	-----------------	----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.